The LAMH Group (Laboratory for Advanced Medicine & Helio Health Group, LAMH) in the Beijing Economic and Technological Development Area (BDA) recently signed a strategic cooperation agreement with Baidu Health.

LAMH and Baidu Health sign a strategic cooperation agreement. [Photo/kfqgw.beijing.gov.cn] 

As an enterprise focusing on early screening and diagnosis of cancer, LAMH relies on patented technologies such as DNA methylation technology and AI algorithms, has established close cooperation with many top cancer centers, universities and their affiliated hospitals, and established a full product pipeline for early screening and early diagnosis of liver cancer, colorectal cancer, lung cancer and pan-cancer species.

In terms of early cancer screening and diagnosis, compared with traditional detection methods, LAMH can detect the occurrence and development of liver cancer earlier and more accurately, and can monitor the whole process, including early screening, early auxiliary diagnosis, curative effect monitoring, and prognosis evaluation and recurrence follow-up, to promote the accuracy of early cancer screening.

Meanwhile, Baidu Health has built a whole service process from registration to consultation, purchasing medicine, and health management, covering the whole cycle of users' health needs.

In the future, LAMH will continue to work with partners such as Baidu Health to build a sustainable Internet health ecosystem and further facilitate the early detection, diagnosis and treatment of cancer.